Press Release

Purpose In a comparator study, designed with assistance from the Food and Drug Administration, a State-of-the-Art (SOTA) ECG device augmented with automated analysis, the comparator, was compared with breakthrough technology, Cardio-HART (CHART). Methods The referral decision defined by physician reading biosignal-based ECG or CHART report were compared for 550 patients, where its performance is calculated against...

CE-marked approval could change the work of specialists and allow them, at the end of the pandemic, to manage the wave of new heart patients After fifteen years of work and CE Mark approval, the Cardio-HART™ or CHART revolutionary cardiac diagnostic device has arrived on the market. Just in time to address all Covid-19 associated heart...

A differenza di altri dispositivi di monitoraggio a distanza, CHART è approvato per l'uso nelle cure primarie, fin dal primo contatto che il paziente ha con il sistema sanitario. Cardio-HART™ o "CHART" è un innovativo dispositivo di diagnostica cardiaca che ha ottenuto l'approvazione CE, giusto in tempo per affrontare l'eredità della cardiopatia associata al COVID-19 e...

Unlike other remote monitoring devices, CHART is approved for use in Primary Care, from the first contact the patient has with the health system. Cardio-HART™ or "CHART" is an innovative cardiac diagnostic device that has been CE approved, just in time to address the legacy of COVID-19-associated cardiac disease and help reduce the overwhelming waiting lists....

Cardio-HART™, a Breakthrough Heart Diagnostic device is CE Marked, just in time to address Europe’s Pandemic consequences of COVID-19. Just in time to meet the consequences of COVID-19 caused heart disease, CHART has obtained CE Mark certification for use in the EU.  With Europe’s vaunted medical systems strained to a breakpoint as a result of COVID-19, they...

for immediate release Toronto, Canada. On December 14th, Cardio-Phoenix Inc. received a 510 (k) clearance for its Cardio-TriTest™ v6.5 medical device from the U.S Food and Drug Administration (FDA). This is the second 510k the company has received, the first being issued June 3rd, 2015. The Cardio-TriTest™ (CTT) device is a non-invasive medical device that collects 3...

Cardio-Phoenix Inc. -  Now ISO 13485:2016 Certified Cardio–Phoenix Inc. is proud to announce that it has received the coveted ISO 13845:2016 certification for the Design and Development of non-invasive diagnostic medical devices. ISO certification of Cardio-Phoenix demonstrates the company’s quality commitment to developing advanced products and novel technology for the early detection of a broad range of...